Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not

Tuberculosis
Graham A W RookAlimuddin Zumla

Abstract

New vaccine candidates for tuberculosis are beginning to enter clinical trials. In this review we discuss issues surrounding the design of these candidates, and the way they were screened in animal models. First, screening vaccines for their ability to attenuate inevitably fatal tuberculosis in immunologically naïve mice might be leading to the selection of inappropriate candidates. We need to screen vaccines for their ability to stop the development of progressive disease, since this is what they must achieve in man. A solution to this problem is proposed. Secondly, we point out that some mouse models of tuberculosis in laboratories in developing countries, where exposure to environmental mycobacteria is large, mimic neglected aspects of human disease more closely than do low-dose infections in hyper-susceptible immunologically naïve mice in the USA or Europe. We need to think more about geographical differences in immunological experience, and these mouse models can help us. Thirdly, we conclude that in developing countries where BCG fails this is not because there is too little Th1 response, but rather because the Th1 response is rendered ineffective and immunopathological by other subversive mechanisms, including IL-4 respo...Continue Reading

References

Apr 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M E WilsonG A Colditz
Mar 2, 1994·JAMA : the Journal of the American Medical Association·G A ColditzF Mosteller
Feb 1, 1993·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·M LagranderieD W Smith
Apr 29, 1998·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·D StrachanH Williams
Apr 5, 2000·Journal of Pediatric Gastroenterology and Nutrition·E LindbergH Hildebrand
May 3, 2000·The Journal of Clinical Investigation·V A BoussiotisA E Goldfeld
Aug 23, 2001·Advanced Drug Delivery Reviews·S S Davis
Sep 18, 2001·Lancet·L C Stene, P Nafstad
Apr 20, 2002·Science·Maria YazdanbakhshRonald van Ree
May 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·Julio C DelgadoAnne E Goldfeld
Sep 20, 2002·The New England Journal of Medicine·Jean-Francois Bach
Nov 28, 2002·Diabetes·Edwin A M Gale
Dec 24, 2002·Infection and Immunity·Carrie J Riendeau, Hardy Kornfeld
Jan 4, 2003·Nature Reviews. Immunology·Siamon Gordon
Apr 18, 2003·Clinical and Experimental Immunology·G MazzarellaA Sanduzzi
Jun 20, 2003·Journal of Proteome Research·Anatoly M VasilievVyacheslav M Abramov
Sep 4, 2003·The Journal of Experimental Medicine·Martin I VoskuilGary K Schoolnik
Nov 25, 2003·The British Journal of Dermatology·P D Arkwright, T J David
Mar 10, 2004·Springer Seminars in Immunopathology·G A W RookL Rosa Brunet
Apr 7, 2004·The Journal of Experimental Medicine·Vissia VigliettaDavid A Hafler
May 1, 2004·The Journal of Experimental Medicine·Martin A KriegelHanns-Martin Lorenz

❮ Previous
Next ❯

Citations

Mar 25, 2014·Tuberculosis Research and Treatment·Michael Eisenhut, Katy Fidler
Dec 13, 2007·Proceedings of the American Thoracic Society·John GouldingTracy Hussell
Sep 2, 2011·The Journal of Infectious Diseases·Maeve K LalorHazel M Dockrell
Nov 17, 2007·The Journal of Infectious Diseases·E van RietM Yazdanbakhsh
Dec 8, 2010·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Madhan Kumar MurthyAlamelu Raja
Sep 4, 2012·Trends in Molecular Medicine·Uthaman GowthamanJaved N Agrewala
Oct 5, 2010·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Afzal R MohammedYvonne Perrie
Mar 2, 2010·Tuberculosis·Denise Morais FonsecaVânia Luiza Deperon Bonato
Oct 13, 2009·The Journal of Allergy and Clinical Immunology·Jeroen HolEdward E Nieuwenhuis
Apr 24, 2009·Theoretical Population Biology·N B Mantilla-Beniers, M G M Gomes
Feb 19, 2009·Seminars in Immunology·Erika WissingerTracy Hussell
May 25, 2007·The Lancet Infectious Diseases·Madhukar PaiRichard O'Brien
Jan 20, 2007·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Xinchun ChenEmmanuel Katsanis
Jun 20, 2015·Human Vaccines & Immunotherapeutics·Amanda M Jamieson
Apr 27, 2010·Respirology : Official Journal of the Asian Pacific Society of Respirology·Keertan DhedaYing Zhang
Nov 28, 2009·Vaccine·Maeve K LalorHazel M Dockrell
Jun 15, 2010·PLoS Neglected Tropical Diseases·Fabiani G FrantzLúcia H Faccioli
Oct 10, 2006·Clinical and Vaccine Immunology : CVI·S C OlsenW R Waters
Feb 23, 2019·BioMed Research International·Yan Yang, Jianqing Wu
Jun 9, 2020·Frontiers in Immunology·Sajid NadeemJaved N Agrewala
Mar 23, 2021·Frontiers in Immunology·Emmanuella DriciruMeta Roestenberg

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.